Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target

Aug 26, 2026, 12:10 PMBenzinga Newsdesk

HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharmaceuticals (NASDAQ:PHIO) with a Buy and maintains $14 price target.

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 11, 2026, 11:13 AMBenzinga Newsdesk
Phio Pharmaceuticals Receives US Notice Of Allowance For Patent Covering PH-894, Further Strengthening Company's IP Portfolio
PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative and infectious diseases in U.S.King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio
Read original at benzinga
PHIO
SEC EDGARJul 21, 2026, 11:07 AMSEC EDGAR
8-K filing — Phio Pharmaceuticals Corp. (PHIO)
Filed: 2026-07-21 AccNo: 0001437749-26-023916 Size: 184 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgar
PHIO
BenzingaJul 15, 2026, 11:06 AMBenzinga Newsdesk
Phio Pharmaceuticals Announces Multiple Favorable Patent Actions Encompassing Three Notices Of Allowance And One Grant Decision
The company has received multiple favorable patent actions encompassing three notices of allowance and one grant decision to further strengthen Phio's global intellectual property portfolio in the United States,
Read original at benzinga
PHIO